Mode
Text Size
Log in / Sign up

Case report finds West Nile virus encephalitis in immunocompromised child after transfusionsCase report links West Nile virus infection to blood transfusions in Saudi Arabia

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider WNV as a potential transfusion risk for immunocompromised patients in endemic areas.

This case report with cross-sectional donor screening describes a 4-year-old Saudi girl with Ewing's sarcoma undergoing chemotherapy at a tertiary hospital in Jeddah. The patient developed West Nile virus (WNV) encephalitis following multiple blood transfusions. Serological screening of the 30 implicated donors found 4 (13.3%) tested positive for anti-WNV antibodies, indicating prior exposure. The patient's WNV infection was confirmed by polymerase chain reaction. The patient developed WNV encephalitis as a serious adverse event; other safety and tolerability data were not reported. Key limitations include the lack of retrospective molecular testing of the implicated blood units, meaning transfusion is described as a plausible but unconfirmed transmission route. The study is a single case report, and findings should not be generalized to all immunocompromised patients or regions. The authors suggest the case underscores the need to consider nucleic acid testing for WNV RNA in pretransfusion screening for high-risk recipients, particularly during peak transmission periods.

Doctors in Saudi Arabia reported on a 4-year-old girl with cancer who developed a serious brain infection from West Nile virus after receiving multiple blood transfusions. The patient was undergoing chemotherapy for Ewing's sarcoma, which weakened her immune system. When tested, she was positive for West Nile virus.

The doctors then tested blood samples from the 30 donors who provided her transfusions. They found that 4 of those 30 donors (13.3%) had antibodies in their blood showing they had been exposed to West Nile virus in the past. This suggests the virus could have come from one of the donated blood units.

It is important to be careful with these results. This is a report of just one patient. The doctors could not test the actual donated blood bags for the virus, so they cannot say for certain that the transfusion caused the infection. The finding does highlight that West Nile virus exposure exists in some donor populations and that patients with weak immune systems are at higher risk for serious illness.

Readers should understand this is an early observation, not proof. It reminds doctors to be aware of West Nile virus risks when giving blood to vulnerable patients, especially in areas where the virus is present.

What this means for you:
A single case suggests West Nile virus may spread via blood transfusion; more research is needed to confirm.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
West Nile virus (WNV), an emerging mosquito-borne flavivirus, is a growing global concern, particularly in tropical regions, where climatic conditions favor vector proliferation. Although often asymptomatic, less than 1% of cases develop severe neuroinvasive disease, primarily among the elderly or immunocompromised. Transfusion-transmitted WNV infections have been documented but remain underrecognized in the Middle East. This study reports a case of a 4-year-old Saudi girl with Ewing’s sarcoma undergoing chemotherapy who developed WNV encephalitis following multiple blood transfusions from 30 healthy blood donors. The investigation was conducted at a tertiary hospital in Jeddah. Serological screening of 30 blood donors was performed to identify potential sources of infection. The patient presented with febrile seizures, and MRI findings of bilateral thalamic and midbrain signal changes were consistent with viral encephalitis. WNV infection in the patient was confirmed by the polymerase chain reaction. The clinical picture correlated with reported cases of transfusion-associated WNV infection in immunocompromised hosts. Four of the 30 donor samples (13.3%) tested positive for anti-WNV antibodies, indicating prior exposure among donors and supporting transfusion as a plausible but unconfirmed transmission route, as retrospective molecular testing of implicated blood units was not available. This case underscores the need to consider the incorporation of nucleic acid testing (NAT) for WNV RNA into pretransfusion screening protocols, particularly for high-risk recipients and during peak transmission periods, to reduce the risk of transfusion-transmitted infection. The detection of anti-WNV antibodies among healthy donors highlights the silent viral circulation in the community. Strengthening national surveillance systems, enhancing vector control measures, and improving clinician awareness are vital to mitigate transfusion-related WNV transmission in endemic and emerging regions.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.